With more than 15 years of experience in working with entrepreneurs to advance medicine through innovation and technology, Ciechanover most recently served as the executive director of business development at Celgene Corporation.
Before Celgene, Ciechanover managed business development and planning for Amylin Pharmaceuticals.
Prior to Amylin, he drove life sciences venture capital efforts for Pequot Ventures, and earlier analyzed and vetted acquisition candidates at Pfizer Inc.
Ciechanover has an MBA from Harvard Business School, an MD from Weill Cornell University Medical College, a master’s degree in Epidemiology from the University of Cambridge and a bachelor’s degree in Psychology from Stanford University. He is a contributor to the Multiple Myeloma Research Foundation and Project Smile.
Commenting on the new role, Ciechanover was quoted as saying: “KPCB has a history of supporting cutting-edge advancements in the life sciences and is known as a highly strategic resource for entrepreneurs, medical professionals and scientists.
“I look forward to working with a group of professionals I’ve long respected.
“I am eager to begin supporting entrepreneurs and companies that can change the face of medicine”, he added.